

6 March 2015

Company Announcements Office  
Australian Securities Exchange

## **Nanosonics recognised for outstanding Australian innovation**

Nanosonics (ASX:NAN), is pleased to announce that Ron Weinberger, President of Technology and Innovation, has been awarded the Innovation Hero Medal from The Warren Centre and the University of Sydney.

The Innovation Hero Award recognises outstanding innovations in engineering technology. It is awarded to Australian-based people or teams that successfully develop a new technology into a commercial product or service and create great benefit for Australia. Dr Weinberger led the team development and commercialisation of the ultrasonic nano-nebulisation trophon technology used in Nanosonics' trophon<sup>®</sup> EPR device.

The trophon technology utilises ultrasonic nano-nebulisation to produce a hydrogen peroxide mist for high level disinfection (HLD) of ultrasound transducers. The trophon EPR device is fully automated and solves many of the issues of traditional HLD processes that typically involve low level disinfectant wipes or soaking in containers of potentially harmful chemicals.

"This is exactly the type of technical advance that the Warren Centre is proud to recognise for contributing to a higher quality of life," said Ashley Brinson, Executive Director, The Warren Centre for Advanced Engineering. "There is a rich history of technical and commercial success among former biomedical Innovation Hero Award recipients. Nanosonics stands among a number of excellent biomedical innovation peers such as ResMed and Cochlear."

The trophon EPR is now available in all major global markets and achieving widespread adoption in hospitals and healthcare facilities. The growing adoption rate is due to a number of factors that are strengthening the market fundamentals, including mounting clinical evidence and ongoing changes to disinfection guidelines. These strengthening fundamentals are also creating a growing opportunity to establish trophon EPR globally as the new standard of care.

"We're delighted that Dr Weinberger and his team are being recognised by this prestigious award," said Michael Kavanagh, Nanosonics Chief Executive Officer and President. "The trophon technology is an example of true innovation, where real unmet needs are being effectively met through the implementation of a new solution. The trophon EPR effectively addresses the need for improved infection control solutions in the ultrasound field around the world."

“We are now focusing our R&D and engineering efforts on a second generation trophon device and new applications for the trophon platform technology together with chemistries to address unmet needs that exist in infection control.”

Dr Weinberger and representatives from his team attended a luncheon event on 4 March in Sydney to officially receive the award.

**Michael Kavanagh**  
**CEO / President**

**For more information please contact:**

Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600

Kyahn Williamson, Investor Relations, Buchan Consulting on (03) 9866 4722

Ben Oliver, Media Relations, Buchan Consulting on (03) 9866 4722.

**About Nanosonics**

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries. For more information about Nanosonics please visit [www.nanosonics.com.au](http://www.nanosonics.com.au)